Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EOS-448, GSK4428859, belrestotug
EOS884448 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Multiple Ascending Dose | EXPERIMENTAL | Dose escalation according to cohort allocation |
| Name | Type | Description |
|---|---|---|
| EOS884448 | DRUG | Multiple Ascending Dose |
Inclusion Criteria: 1. Be willing to provide a signed written informed consent for the trial and consent for biopsies before and during administration of EOS884448 2. Be more than18 years of age on day of signing informed consent. 3. Have histologically or cytologically confirmed advanced or metast...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
EOS884448 is an investigational small molecule developed by iTeos Therapeutics, Inc. for the treatment of advanced cancer. It is designed to target TIGIT, a protein involved in immune regulation. The drug has completed a Phase 1 clinical trial and is not currently approved for any indication.
EOS884448 targets TIGIT, a protein that acts as an immune checkpoint. By binding to TIGIT, the drug aims to enhance anti-tumor immune responses. This mechanism is being explored in advanced cancer settings.
EOS884448 is being developed by iTeos Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol ITOS. The company focuses on discovering and developing novel immuno-oncology therapies.
EOS884448 has completed a Phase 1 clinical trial. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Further clinical development may be ongoing or planned.
EOS884448 was evaluated in a first-in-human Phase 1 study, NCT04335253, titled 'First-In-Human Study of EOS884448 in Participants with Advanced Cancers.' The trial enrolled 40 participants in Belgium and has been completed. It was an uncontrolled, non-randomized study.